- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03729791
The Effect of tDCS on Schizophrenia With Negative Symptoms
Clinical Trials for Neuroimaging and Electrophysiology in Schizophrenic Patients With Negative Symptoms Using Transcranial Direct Current Stimulation
Descripción general del estudio
Descripción detallada
The project will investigate the use of a novel technique, transcranial direct current stimulation (tDCS) in the treatment of patients with schizophrenia. tDCS permit the application of an extremely weak continuous electrical current to the brain through an anode and a cathode applied on the scalp. Anodal stimulation appears to increase brain activity whereas cathodal stimulation has the opposite effect.
Using anodal and cathodal tDCS the investigators aimed to treat negative symptoms of schizophrenia. The investigators plan to apply tDCS such that it can simultaneously increased activity in the frontal brain areas and reduce activity over temporoparietal cortex, 2 areas involved in the physiopathology of the disease. Real active stimulation will be compare to a sham condition in 44 patients (22 in each group). 44 patients will be included in Seoul National University Hospital
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Seoul, Corea, república de
- Seoul National University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- DSM-IV Schizophrenia
- 1 or more items of Negative symptom score in PANSS > 5
Exclusion Criteria:
- presences of neurological disorder or history
- IQ < 70
- presence of severe personality disorders
- presence of substance use disorder (except nicotin)
- pregnancy
- presence of severe medical condition or disorders
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: actual tDCS
2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
|
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head.
It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
|
Comparador activo: sham tDCS
sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
|
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head.
It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Positive and Negative Syndrome Scale (PANSS)
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in psychopathology To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted.
The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
The Clinical Assessment Interview for Negative Symptoms (CAINS)
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in psychopathology The CAINS is a clinical rating scale for negative symptoms with potent and clear treatment targets for the next generation of pharmacological and psychosocial treatments.
It rangs between 0 to 52
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - resting
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in lagged phase synchronization and microstate connectivity
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - P300
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in P300
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - MMN
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MMN
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - ERN
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in ERN
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - grey matter volume
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in grey matter volume
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical thickness
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in cortical thickness
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical surface area
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MRI - cortical thickness
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical gyrification
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in cortical gyrification
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - mean diffusivity (MD)
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - axial diffusivity (AD)
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in AD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - radial diffusivity (RD)
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in RD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - fractional anisotropy (FA)
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in FA
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - rsfMRI
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in BOLD signals
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - MRS
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
Changes in concentration of N-Acetyl Aspartate, Creatin, Choline, Myoinositol, Glutamate, Glutamine, GABA metabolite concentration change with treatment
|
approximately 2 weeks (baseline and 2 weeks followups)
|
fNIRS
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in level of the Oxy-Hemoglobin
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Korean Wechsler Adult Intelligence Scale (K-WAIS)
Periodo de tiempo: baseline
|
baseline total Intelligence quotient value
|
baseline
|
Spatial Working Memory
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in the spatial working memory ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
California Verbal Learning Test
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in verbal learning ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Letter/Category fluency test
Periodo de tiempo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in fluency ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Tae Young Lee, MD, Seoul National University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1.001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre tDCS
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía...Inscripción por invitaciónTrastornos relacionados con sustanciasEspaña
-
Hôpital le VinatierTerminadoEsquizofrenia | Alucinaciones auditivasFrancia, Túnez
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Desconocido
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)TerminadoActividad del motor | Neuroplasticidad motoraEstados Unidos
-
Charite University, Berlin, GermanyTerminadoMigraña Con Aura | CADASIL | Microangiopatía cerebral | Estenosis de la ACIAlemania
-
Bambino Gesù Hospital and Research InstituteTerminado
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)TerminadoTrastorno depresivo mayorEstados Unidos
-
University of MichiganNational Institute of Mental Health (NIMH)TerminadoTrastorno de estrés postraumático (TEPT)Estados Unidos
-
Universidade Federal de PernambucoTerminado
-
Thorsten RudroffTerminadoEsclerosis múltiple | Dolor neuropáticoEstados Unidos